[Clinical study of navelbine combined with cisplatin in the treatment of advanced non-small cell lung cancer].
BACKGROUND
To evaluate the efficacy and toxicity of combination chemotherapy with navelbine (NVB) and cisplatin (DDP) in the treatment of advanced non-small cell lung cancer (NSCLC).


METHODS
From 1998 to 2003, 46 patients with advanced NSCLC were treated with NVB plus DDP. NVB was given at a dose of 25 mg/m² on day 1 and 8, DDP at a dose of 65-80 mg/m² on day 1 or days 1-3. Twenty-one days was one cycle, each patient was treated at least for two cycles.


RESULTS
The overall response rate (RR) was 47.8% (22/46), 51.6% (16/31) for the first treated cases and 40.0% (6/15) for the retreated cases. RR of stage IIIB and IV was 54.5% (12/22) and 41.7% (10/24) respectively. RR for adenocarcinoma and squamous cell carcinoma was 50.0% (14/28) and 44.4% (8/18) respectively. The median survival time was 9.5 months. One-year survival rate was 39.1%. The common toxicities were myelosuppression, nausea/vomiting and phlebitis. Neutropenia accounted for 95.7% (grade III+IV was 28.3%), nausea/vomiting for 47.8% (grade III+IV was 8.7%) and phlebitis for 19.6%, but the last one were mild.


CONCLUSIONS
Combination chemotherapy with NVB and DDP is an effective regimen to treat advanced NSCLC, and the toxicities are tolerable.
Peking University Shenzhen Hospital, Shenzhen, Guangzhou 518036, P.R.China.
Yanling
Y
He